Publication:
Tocilizumab challenge: A series of cytokine storm therapy experiences in hospitalized COVID-19 pneumonia patients

Simple item page
dc.contributor.authorBorku Uysal, Betul
dc.contributor.authorIkitimur, Hande
dc.contributor.authorYavuzer, Serap
dc.contributor.authorİKİTİMUR, Barış
dc.contributor.authorUYSAL, HARUN
dc.contributor.authorIslamoglu, Mehmet Sami
dc.contributor.authorOzcan, Erkan
dc.contributor.authorAktepe, Emre
dc.contributor.authorYAVUZER, Hakan
dc.contributor.authorCengiz, Mahir
dc.contributor.institutionauthorUYSAL, HARUN
dc.date.accessioned2020-10-22T19:26:13Z
dc.date.available2020-10-22T19:26:13Z
dc.date.issued2020-06-01T00:00:00Z
dc.description.abstractTo recognize the period of exaggerated cytokine response in patients with coronavirus disease 2019 (COVID-19) pneumonia, and to describe the clinical outcomes of using tocilizumab as a treatment option. The data of 12 adult COVID-19 pneumonia patients who were followed in the inpatient clinics of Biruni University Medical Faculty Hospital (Istanbul, Turkey) were retrospectively analyzed. Diagnostic tests, laboratory examinations, clinical findings, and computed tomography of the thorax imaging results were evaluated. A dramatic laboratory and clinical improvement was observed in 83% (10 out of 12) of patients after tocilizumab. In 17% (2 out of 12) of our patients, short-term ventilator support was required in the intensive care unit. The longest hospital stay was 18 days. However, in the end, all of our patients were discharged home with good health. Although arterial oxygen saturations (87.58 +/- 3.12%) dropped in room air in the pre-tocilizumab period, post-tocilizumab they normalized in all patients (94.42 +/- 1%). None of them had fever after tocilizumab treatment and the levels of C-reactive protein (13.08 +/- 12.89) were almost within normal limits. Eosinophil values were quite low at the time of diagnosis (10 +/- 17.06), but increased significantly post-tocilizumab (155.33 +/- 192.69). There is currently no proven treatment for COVID-19 induced by novel coronavirus SARS-CoV-2. Based on our experience with twelve adult COVID-19 pneumonia patients,we can say that tocilizumab, an IL-6 inhibitor, is more beneficial in preventing the damage caused by excessive cytokine response in the body if administered at the right time and provides clinical and radiological recovery.
dc.identifier.citationBorku Uysal B., Ikitimur H., Yavuzer S., İKİTİMUR B., UYSAL H., Islamoglu M. S. , Ozcan E., Aktepe E., YAVUZER H., Cengiz M., -Tocilizumab challenge: A series of cytokine storm therapy experiences in hospitalized COVID-19 pneumonia patients-, JOURNAL OF MEDICAL VIROLOGY, 2020
dc.identifier.doi10.1002/jmv.26111
dc.identifier.pubmed32484930
dc.identifier.scopus85087179272
dc.identifier.urihttp://hdl.handle.net/20.500.12645/24488
dc.identifier.urihttps://onlinelibrary.wiley.com/doi/10.1002/jmv.26111
dc.identifier.wosWOS:000543916500001
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectCOVID-19en
dc.subjectPneumonia
dc.subjectSARS-Cov-2
dc.subjectTocilizumab
dc.titleTocilizumab challenge: A series of cytokine storm therapy experiences in hospitalized COVID-19 pneumonia patients
dc.typeArticle
dspace.entity.typePublication
local.avesis.idbd3a078c-7cc4-49c2-94d0-fc9b173a6801
local.publication.goal03 - Sağlık ve Kaliteli Yaşam
local.publication.isinternational1
relation.isAuthorOfPublication2ff9c417-c920-435c-97f1-59f5f671a74c
relation.isAuthorOfPublication.latestForDiscovery2ff9c417-c920-435c-97f1-59f5f671a74c
relation.isGoalOfPublication9c198c48-b603-4e2f-8366-04edcfc1224c
relation.isGoalOfPublication.latestForDiscovery9c198c48-b603-4e2f-8366-04edcfc1224c
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Tocilizumab challenge A series of cytokine storm therapy experiences in hospitalized COVID‐19 pneumonia patients.pdf
Size:
1.68 MB
Format:
Adobe Portable Document Format
Description:
Download
Collections
Yayınlar - Eserler